PARIS, France and CAMBRIDGE, Mass., United States – May 4, 2026
Nanobiotix has announced FDA acceptance of a protocol amendment to its ongoing global Phase 3 NANORAY-312 clinical trial evaluating JNJ-1900 (NBTXR3) in head and neck cancer, a move that could accelerate clinical timelines and regulatory progress. The amendment, submitted by global sponsor Johnson & Johnson, removes the previously planned interim analysis and revises the final analysis to occur earlier with fewer required events, signaling a strategic effort to speed up study completion and potential approval pathways. This development highlights how adaptive clinical trial design is being used to optimize efficiency in late-stage oncology studies, especially for therapies with strong prior evidence.
Protocol Amendment Targets Faster Clinical Readout
The most critical change in the NANORAY-312 Phase 3 study is the elimination of the interim analysis, which often introduces delays and operational complexity without always adding decisive value. By moving directly to a modified final analysis with fewer required events, Nanobiotix aims to shorten the trial duration while preserving statistical validity, allowing results to be generated earlier than originally planned.
The company expects that the final data readout timeline will now align closely with the previously anticipated interim analysis timing, effectively compressing the development cycle. However, this approach depends heavily on event occurrence rates, meaning timelines are still subject to variability based on patient outcomes during the trial.
NBTXR3 Demonstrates Novel Mechanism in Oncology Trials
Advertisement
The therapy under evaluation, JNJ-1900 (NBTXR3), is a first-in-class nanoparticle-based oncology product designed to enhance the effects of radiotherapy through a physical mechanism of action. Composed of functionalized hafnium oxide nanoparticles, the treatment is administered via a single intratumoral injection and activated by radiation to increase tumor cell destruction while also triggering a systemic immune response.
This dual mechanism is being studied in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) who are not eligible for platinum-based chemotherapy. The therapy has previously demonstrated proof-of-concept in a Phase 2/3 study in soft tissue sarcoma and has received Fast Track designation from the U.S. Food and Drug Administration, supporting its continued clinical development across multiple tumor types.
Global Trial Strategy and Clinical Expansion
Nanobiotix is advancing NBTXR3 through a global clinical development strategy, supported by collaborations with Johnson & Johnson and research institutions such as the MD Anderson Cancer Center, enabling evaluation across multiple cancer indications and therapeutic combinations. The NANORAY-312 study remains the pivotal Phase 3 trial, and its outcome is expected to play a decisive role in regulatory submissions and potential approval. With the protocol amendment now in place, the study is positioned to deliver clinically meaningful data sooner, potentially accelerating access to this innovative radiotherapy-activated treatment for patients with limited options.
Source: Nanobiotix press release
